Xtacy Therapeutics Corp. Stock Deutsche Boerse AG

Equities

TT5

CA98423G1072

Investment Management & Fund Operators

Delayed Deutsche Boerse AG 02:31:15 2024-05-02 am EDT 5-day change 1st Jan Change
0.016 EUR +23.08% Intraday chart for Xtacy Therapeutics Corp. +23.08% +28.00%
Sales 2022 - Sales 2023 - Capitalization 2.46M 2.3M
Net income 2022 -1M -935K Net income 2023 - 0 EV / Sales 2022 -
Net Debt 2022 25.37K 23.71K Net Debt 2023 16.7K 15.61K EV / Sales 2023 -
P/E ratio 2022
-3.97 x
P/E ratio 2023
-4.19 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 89.2%
More Fundamentals * Assessed data
Dynamic Chart
Xtacy Therapeutics Corp. Reports Earnings Results for the First Quarter Ended December 31, 2023 CI
Xtacy Therapeutics Corp. Reports Earnings Results for the Full Year Ended September 30, 2023 CI
Xtacy Therapeutics Corp. Expands MDMA Platform Pharmaceutical Grade Psychedelic Solutions to Solve Unmet Medical Needs CI
Global Wellness Strategies Inc. will Change its Name to XTACY Therapeutics Corp CI
Global Wellness Strategies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023 CI
Global Wellness Strategies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023 CI
Global Wellness Strategies Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022 CI
Global Wellness Strategies Inc. Reports Earnings Results for the Full Year Ended September 30, 2022 CI
Global Wellness Strategies Inc. Auditor Raises 'Going Concern' Doubt CI
Global Wellness Strategies Inc. Announces Formation of Wholly Owned Pharma Subsidiary Focused on Clinical Trials CI
Global Wellness Strategies Effervescent Cannabis Products Approved to Launch GWS Achieves Major Milestone Partnering with Hempsana Holdings CI
Global Wellness Strategies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2022 CI
Global Wellness Strategies Inc. Signs Custom Manufacturing Agreement with Hempsana Holdings CI
Global Wellness Strategies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2022 CI
Global Wellness Strategies Inc. Announces Shanti Therapeutics Mdma Clinical Trial Update CI
More news
1 day+23.08%
1 week+23.08%
1 month+23.08%
3 months-56.76%
6 months+60.00%
Current year+28.00%
More quotes
1 week
0.01
Extreme 0.013
0.02
1 month
0.01
Extreme 0.0055
0.02
Current year
0.01
Extreme 0.0055
0.05
1 year
0.01
Extreme 0.005
0.09
3 years
0.00
Extreme 0.0005
0.33
5 years
0.00
Extreme 0.0005
0.51
10 years
0.00
Extreme 0.0005
2.00
More quotes
Managers TitleAgeSince
Chief Executive Officer - 17-11-29
Director of Finance/CFO 70 19-04-09
Corporate Secretary - -
Members of the board TitleAgeSince
Director of Finance/CFO 70 19-04-09
Chief Executive Officer - 17-11-29
Director/Board Member - 19-10-29
More insiders
Date Price Change
24-05-02 0.016 +23.08%
24-04-30 0.013 -18.75%
24-04-29 0.016 0.00%
24-04-26 0.016 -17.95%
24-04-25 0.0195 +18.18%

Delayed Quote Deutsche Boerse AG, May 02, 2024 at 02:31 am EDT

More quotes
XTACY Therapeutics Corp. is a Canada-based prospect generator that provides high growth companies with financial, operational, and management assistance in the fast-growing market for consumer wellness products. The Company's investment strategy is focused on the specific areas of pain, depression and mental illness. The focus of the Company is on global wellness, psychedelics, mycology, hemp and cannabidiol (CBD), healthcare-related target companies and their clinical studies and trials. By investing in techniques, such as micro-dosing using organic compounds and synthetic molecules, the Company is focusing on the research with the aim of providing wellness benefits with less side effects for people and the planet.
More about the company